Oncotype DX AR-V7 Nucleus Detect® results

What to expect

The AR-V7 Nucleus Detect® test accurately identifies which patients will not respond to androgen receptor (AR)-targeted therapies (such as enzalutamide or abiraterone acetate) and should receive chemotherapy or other therapies instead.

 

 

Understanding your results

Icon minus

AR-V7 negative (AR-V7-):

An AR-V7- result means the test did not find any AR-V7 protein in your circulating tumor cells and your tumor may respond to AR-targeted therapies

Icon plus

AR-V7 positive (AR-V7+):

An AR-V7+ result means that the test did find AR-V7 protein in your cells and your tumor will not respond to AR-targeted therapies. In this case, your doctor will likely suggest another therapy, such as chemotherapy

Your results can change over time

Many mCRPC patients eventually become AR-V7+, and studies show that the likelihood of AR-V7 in the blood increases with each exposure to AR-targeted therapy. As a result, even if your first AR-V7 Nucleus Detect test result is AR-V7-, your doctor may recommend the test after each round of AR-targeted therapy.

Learn how the AR-V7 Nucleus Detect test puts AR-targeted therapy to the test

Learn about the AR-V7 Nucleus Detect testing process

See FAQs about the AR-V7 Nucleus Detect test

98%
AR-V7 Nucleus Detect test patients have $0 financial responsibility*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Your cost-sharing amounts, including deductibles and copays, will vary by plan and coverage type. Only your insurer can confirm if and how the AR-V7 Nucleus Detect test will be covered.

99%
of AR-V7 Nucleus Detect test patients have a financial responsibility of <$100*

This calculation includes patients with Medicare, Medicare Advantage, Medicaid, Managed Medicaid, and commercial insurance. Patients with high-deductible plans may receive a bill for most or all the cost of the Oncotype DX AR-V7 Nucleus Detect test if they have not satisfied their deductible.†

Learn about costs, coverage, and how Exact Sciences can help

 

*The numbers cited are based on historical patient billing data from 1/02/2021 to 12/31/2021. Rates of coverage vary by state and region. Exceptions for coverage may apply. Exact Sciences strongly encourages patients to contact their insurer with questions about AR-V7 Nucleus Detect test coverage.